DZ2639A1 - Composés thérapeutiquement actifs basés sur le remplacement bio-isostérique du catéchol par l'indazole dans des inhibiteurs de PDE4 leur procédé de production et compositions pharmaceutiques les contenant. - Google Patents

Composés thérapeutiquement actifs basés sur le remplacement bio-isostérique du catéchol par l'indazole dans des inhibiteurs de PDE4 leur procédé de production et compositions pharmaceutiques les contenant.

Info

Publication number
DZ2639A1
DZ2639A1 DZ980249A DZ980249A DZ2639A1 DZ 2639 A1 DZ2639 A1 DZ 2639A1 DZ 980249 A DZ980249 A DZ 980249A DZ 980249 A DZ980249 A DZ 980249A DZ 2639 A1 DZ2639 A1 DZ 2639A1
Authority
DZ
Algeria
Prior art keywords
indazole
catechol
bio
pharmaceutical compositions
production process
Prior art date
Application number
DZ980249A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2639A1 publication Critical patent/DZ2639A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ980249A 1997-11-04 1998-11-03 Composés thérapeutiquement actifs basés sur le remplacement bio-isostérique du catéchol par l'indazole dans des inhibiteurs de PDE4 leur procédé de production et compositions pharmaceutiques les contenant. DZ2639A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6416097P 1997-11-04 1997-11-04

Publications (1)

Publication Number Publication Date
DZ2639A1 true DZ2639A1 (fr) 2003-03-08

Family

ID=22053970

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980249A DZ2639A1 (fr) 1997-11-04 1998-11-03 Composés thérapeutiquement actifs basés sur le remplacement bio-isostérique du catéchol par l'indazole dans des inhibiteurs de PDE4 leur procédé de production et compositions pharmaceutiques les contenant.

Country Status (34)

Country Link
US (2) US6716978B2 (fr)
EP (1) EP1040100A1 (fr)
JP (1) JP2001521925A (fr)
KR (1) KR20010031783A (fr)
CN (1) CN1281441A (fr)
AP (1) AP1122A (fr)
AR (1) AR016413A1 (fr)
AU (1) AU754184B2 (fr)
BG (1) BG104391A (fr)
BR (1) BR9813938A (fr)
CA (1) CA2309175A1 (fr)
CZ (1) CZ20001623A3 (fr)
DZ (1) DZ2639A1 (fr)
EA (1) EA200000385A1 (fr)
HN (1) HN1998000172A (fr)
HR (1) HRP20000262A2 (fr)
HU (1) HUP0100330A3 (fr)
ID (1) ID24942A (fr)
IL (1) IL135714A0 (fr)
IS (1) IS5452A (fr)
MA (1) MA26562A1 (fr)
NO (1) NO20002127L (fr)
NZ (1) NZ503995A (fr)
OA (1) OA11353A (fr)
PA (1) PA8462601A1 (fr)
PE (1) PE131099A1 (fr)
PL (1) PL340799A1 (fr)
SK (1) SK6262000A3 (fr)
TN (1) TNSN98199A1 (fr)
TR (1) TR200001256T2 (fr)
UY (1) UY25232A1 (fr)
WO (1) WO1999023076A1 (fr)
YU (1) YU25400A (fr)
ZA (1) ZA9810042B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
HUP0004150A3 (en) * 1997-11-04 2001-08-28 Pfizer Prod Inc Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
ES2427930T3 (es) * 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
CA2506949A1 (fr) * 2002-11-27 2004-06-10 Altana Pharma Ag Inhibiteurs de pde4 et pde3/4 que l'on utilise dans le traitement de la cachexie
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
CN104803974A (zh) * 2004-03-03 2015-07-29 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
CA2584317A1 (fr) * 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Derives de pyrazole utilises en tant qu'inhibiteurs de phosphodiesterase 4
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
EP1928866A1 (fr) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Indazoles substitues utilises en tant qu'inhibiteurs de phosphodiesterase de type-iv
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
WO2007084841A2 (fr) 2006-01-13 2007-07-26 Wyeth 1h-indoles substitues par un groupe sulfonyle en tant que ligands pour les recepteurs de la 5-hydroxytryptamine
KR101357465B1 (ko) 2006-01-31 2014-02-03 어레이 바이오파마 인크. 키나제 억제제 및 그의 사용 방법
DK2124944T3 (da) 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
WO2009067597A1 (fr) * 2007-11-21 2009-05-28 Decode Genetics Ehf Dérivés de catéchols substitués en position 4 (ou 5)
CA2722923C (fr) 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Composes indazole comme antagonistes des recepteurs ccr1
JP5411927B2 (ja) * 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
EP2346868B1 (fr) * 2008-09-26 2016-01-27 Boehringer Ingelheim International Gmbh Composés azaindazole en tant qu antagonistes des récepteurs ccr1
EP2491028B1 (fr) 2009-10-21 2013-12-11 Boehringer Ingelheim International GmbH Composés indazole et pyrazolopyridine comme antagonistes du récepteur ccr1
EP2493875B1 (fr) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1
CA2782384A1 (fr) * 2009-12-08 2011-06-16 Boehringer Ingelheim International Gmbh Procede de synthese d'intermediaires utiles pour la fabrication de for composes a substitution indazole et aza-indazole
TWI487697B (zh) * 2009-12-23 2015-06-11 Palau Pharma Sa 作為組織胺ｈ受體拮抗劑之胺基烷基嘧啶衍生物類
WO2011137109A1 (fr) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Composés azaindazole amides en tant qu'antagonistes des récepteurs ccr1
CA2799154A1 (fr) 2010-05-12 2011-11-17 Abbvie Inc. Inhibiteurs indazoliques des kinases
EP2655371B1 (fr) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Composés de pyrazolopipéridine en tant qu'antagonistes de récepteur ccr1
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
BR112017000762A2 (pt) 2014-07-15 2017-11-21 Gruenenthal Gmbh derivados de azaspiro(4.5)decano substituído.
US12582809B2 (en) 2018-01-26 2026-03-24 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021138391A1 (fr) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole
US11457370B2 (en) 2020-12-11 2022-09-27 Hewlett Packard Enterprise Development Lp System and method for seamless live upgrade of access points using neighbor data
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
CN116003325B (zh) * 2023-01-09 2025-04-25 南方医科大学 吲唑类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064304A1 (de) * 1970-12-29 1972-07-20 Agfa-Gevaert Ag, 5090 Leverkusen Lichtempfindliches farbfotografisches Material
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
CN1080260C (zh) * 1996-06-25 2002-03-06 美国辉瑞有限公司 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途
EP0816357B1 (fr) * 1996-06-27 2002-01-09 Pfizer Inc. Dérivés d'indazole substitués
US6262040B1 (en) * 1996-09-04 2001-07-17 Pfizer Inc Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
PT983249E (pt) * 1997-05-08 2002-08-30 Pfizer Prod Inc Procesos e intermediarios para a preparacao de derivados de indazole substituidos
HUP0004150A3 (en) * 1997-11-04 2001-08-28 Pfizer Prod Inc Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AU754184B2 (en) 2002-11-07
BR9813938A (pt) 2000-09-26
AU9277798A (en) 1999-05-24
HN1998000172A (es) 1999-01-08
AR016413A1 (es) 2001-07-04
US6716978B2 (en) 2004-04-06
BG104391A (en) 2000-12-29
AP9801376A0 (en) 1998-12-31
IL135714A0 (en) 2001-05-20
US20020058687A1 (en) 2002-05-16
TR200001256T2 (tr) 2000-11-21
CA2309175A1 (fr) 1999-05-14
EA200000385A1 (ru) 2000-10-30
KR20010031783A (ko) 2001-04-16
HUP0100330A3 (en) 2002-03-28
TNSN98199A1 (fr) 2005-03-15
ZA9810042B (en) 2000-05-03
AP1122A (en) 2002-11-29
JP2001521925A (ja) 2001-11-13
HUP0100330A2 (hu) 2002-02-28
YU25400A (sh) 2003-07-07
HRP20000262A2 (en) 2000-10-31
NZ503995A (en) 2003-02-28
WO1999023076A1 (fr) 1999-05-14
PE131099A1 (es) 1999-12-17
NO20002127L (no) 2000-07-03
IS5452A (is) 2000-04-14
CN1281441A (zh) 2001-01-24
CZ20001623A3 (cs) 2001-08-15
OA11353A (en) 2003-12-19
PL340799A1 (en) 2001-02-26
PA8462601A1 (es) 2000-05-24
UY25232A1 (es) 2000-12-29
US20030158189A1 (en) 2003-08-21
MA26562A1 (fr) 2004-12-20
EP1040100A1 (fr) 2000-10-04
SK6262000A3 (en) 2002-03-05
NO20002127D0 (no) 2000-04-26
ID24942A (id) 2000-08-31

Similar Documents

Publication Publication Date Title
DZ2639A1 (fr) Composés thérapeutiquement actifs basés sur le remplacement bio-isostérique du catéchol par l'indazole dans des inhibiteurs de PDE4 leur procédé de production et compositions pharmaceutiques les contenant.
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
DZ3020A1 (fr) Acides oxamiques nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2718136B1 (fr) Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2753A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
DZ2581A1 (fr) Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2128A1 (fr) Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2227A1 (fr) Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.
DZ3042A1 (fr) Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26571A1 (fr) Derives d'acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26526A1 (fr) Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26430A1 (fr) 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2414A1 (fr) 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.